Checkpoint Inhibitors in Squamous Non-Small Cell Lung Cancer (NSCLC)
Journal Title: Open Access Journal of Oncology and Medicine - Year 2018, Vol 2, Issue 3
Abstract
Checkpoint inhibitors have demonstrated efficacy in squamous NSCLC with tolerable toxicity profile. They are used as a monotherapy, in combination with chemotherapy or following chemo-radiotherapy as a first line, second line or consolidation therapy. As a first line, Pembrolizumab improves outcome (PFS) as a monotherapy in patients with PD-L1 expression of ≥ 50% (HR; 0.35). When used with chemotherapy, it improves PFS (HR; 0.56) irrespective of PD-L1 expression level. Nivolumab also improves PFS (HR; 0.62), when used as a second line for those progressing with chemotherapy. Durvalumab improves PFS (HR; 0.68) when used following chemo-radio therapy as a consolidation therapy. Lung cancer remains the most common cancer diagnosis and the leading cause of cancer-related deaths, with approximately 1.8 million new cases and 1.59 million deaths accounting every year worldwide [1]. Non-small cell lung cancer (NSCLC) covers the 80% of these lung cancer cases and mainly includes two large histological subsets, adenocarcinoma and squamous non-small cell lung cancer (Sq NSCLC) Clinically also Sq NSCLC differs remarkably from adenocarcinoma as it is located more centrally, and arise segmentally involving lobar or main bronchi and often having central cavitation. There is difference in molecular markers also. Based on molecular changes targeted therapies have been developed for subtypes of adenocarcinoma of lung e.g. EGFR inhibitors. Their use is associated with improved outcome with better tolerability. However, such advances have not taken place in management of Sq NSCLC and the conventional platinum-based chemotherapy remained the first line and second line option for patients with Sq NSCLC till recently. Necitumab approved for Sq NSCLC did not became popular due to its side effect profile and limited benefit [2]. Introduction and development of checkpoint inhibitors has changed the management of Sq NSCLC. Checkpoint inhibitors have been evaluated in NSCLC in whole spectrum ranging from neoadjuvant to third line settings and has been indicated as first line, second line and consolidation therapy [2,3]. In this review, information related to use of check point inhibitor in the treatment of Sq NSCLC is presented.
Authors and Affiliations
Bakulesh Khamar
Keywords
Related Articles
- EP ID EP589149
- DOI 10.32474/OAJOM.2018.02.000140
- Views 109
- Downloads 0
Studies on Hybridization and Genetic Diversity in Cowpea (Vigna Unguiculata L)
Crossability of various accessions of cowpea on the basis of pollen development and fruit set was studied along with genetic diversity by SSR markers. There was a significant correlation between fruit set and percent via...
Targeting the Immune Checkpoint in Cancer: Is This a Viable Treatment Option for AML?
The immune suppressive mechanisms displayed by malignant cells are considered a central process in the pathogenesis of cancer. Research in this area has gained significant momentu mover the past 20 years, with several im...
Main Components of Liquid Biopsy are Greater than it Seems?
Long time ago it was wrongly thought that tumor genes and cells are only existence in the exact tumor site. In spite of the fact of the hypothesis that circulating tumor cells (CTCs) are a fundamental prerequisite to met...
Effect of Maize Production in a Changing Climate: Its Impacts, Adaptation, and Mitigation Strategies through Breeding
Increasing the population and off them living styles effect on the surrounding environment leads to changes in climate with time. In the long run, the climatic change could affect agriculture in several ways such as quan...
Re-Purposing Evodiamine as an Anti-Cancer Drug: Effects on Migration and Apoptosis
Introduction: Evodiamine is a quinolone alkaloid compound obtained from a fruit described in traditional Chinese medicine. It has been in use for many centuries for the treatment of headaches, menstrual problems, abdomin...